Based on the Kaleido Biosciences Inc stock forecast from 0 analysts, the average analyst target price for Kaleido Biosciences Inc is not available over the next 12 months. Kaleido Biosciences Inc’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Kaleido Biosciences Inc is Slightly Bearish, which is based on 2 positive signals and 4 negative signals. At the last closing, Kaleido Biosciences Inc’s stock price was USD 0.00. Kaleido Biosciences Inc’s stock price has changed by +0.00% over the past week, +0.00% over the past month and +0.00% over the last year.
No recent analyst target price found for Kaleido Biosciences Inc
No recent average analyst rating found for Kaleido Biosciences Inc
Company Overview Kaleido Biosciences Inc
Kaleido Biosciences, Inc., a clinical-stage healthcare company, develops microbiome metabolic therapies. The company develops KB195 for the treatment of patients with urea cycle disorder; KB295 to treat ulcerative colitis; KB174 for the treatment of hepatic encephalopathy; and KB109 to treat COVID-19 disease. It also develops programs for the treatment of multi drug resistant infection, chronic kidney disease, atherosclerotic cardiovascular disease, cardio-metabolic syndrome, immuno-oncology, and inflammatory bowel diseases. The company has collaboration agreements with Institute Gustave Roussy, Washington University, and Janssen. Kaleido Biosciences, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts. Read Less
Kaleido Biosciences, Inc., a clinical-stage healthcare company, develops microbiome metabolic therapies. The company develops KB195 for the treatment of patients with urea cycle disorder; KB295 to treat ulcerative colitis; KB174 for the treatment of hepatic encephalopathy; and KB...Read More
Frequently Asked Questions About Kaleido Biosciences Inc (KLDO) Stock
Stock Target Advisor's fundamental analysis for Kaleido Biosciences Inc's stock is Slightly Bearish.
Unfortunately we do not have enough data on KLDO's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on KLDO's stock to indicate what its average analyst target is.
Unfortunately we do not have enough data on KLDO's stock to indicate if its overvalued.
The last closing price of KLDO's stock was USD 0.00.
The most recent market capitalization for KLDO is USD 4.26K.
Unfortunately we do not have enough analyst data on KLDO's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Kaleido Biosciences Inc's stock.
As per our most recent records Kaleido Biosciences Inc has 76 Employees.
Kaleido Biosciences Inc's registered address is 65 Hayden Avenue, Lexington, MA, United States, 02421.
You can get more information about it from Kaleido Biosciences Inc's website at https://kaleido.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Underpriced compared to book value
The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
What not to like
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Low market capitalization
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
Highly leveraged
The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Frequently Asked Questions About Kaleido Biosciences Inc (KLDO) Stock
Stock Target Advisor's fundamental analysis for Kaleido Biosciences Inc's stock is Slightly Bearish.
Unfortunately we do not have enough data on KLDO's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on KLDO's stock to indicate what its average analyst target is.
Unfortunately we do not have enough data on KLDO's stock to indicate if its overvalued.
The last closing price of KLDO's stock was USD 0.00.
The most recent market capitalization for KLDO is USD 4.26K.
Unfortunately we do not have enough analyst data on KLDO's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Kaleido Biosciences Inc's stock.
As per our most recent records Kaleido Biosciences Inc has 76 Employees.
Kaleido Biosciences Inc's registered address is 65 Hayden Avenue, Lexington, MA, United States, 02421.
You can get more information about it from Kaleido Biosciences Inc's website at https://kaleido.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for KLDO !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
